Illumina Stock Gains Amid Report of New Bid from Roche | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Illumina's stock rose as much as 9 percent today following a report that the San Diego-based genetic analysis tools firm and Roche may have agreed to a deal for Roche to acquire Illumina for $66 per share, or approximately $8.14 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.